title: Extralipid effects of micronized fenofibrate in dyslipidemic patients.
abstract: The aim of this study was to evaluate the levels of lipid and extralipid parameters in patients with atherogenic dyslipidemia. We investigated the lipid-lowering therapeutic efficacy of fenofibrate and its extralipid influence on oxidized low-density lipoprotein (oxLDL), C-reactive protein (CRP), Fibrinogen, factor VII and plasminogen activator type 1 (PAI-1) during 1-month treatment. Fourteen individuals with HLPIIb were treated with micronized fenofibrate (267 mg/d) for 1 month. The control group included twelve volunteers. Lipidograms were determined with enzymatic kits. ELISA method was used to measure oxLDL and PAI-1. Plasma CRP levels were measured spectrophotometrically. Fibrinogen and factor VII serum levels were evaluated with automatic coagulometer. After 1-month therapy with micronized fenofibrate, we observed a significant reduction of total cholesterol (TC) (277.2 to 217.8 mg/dl, p < 0.05), LDL (183.6 to 129.4 mg/dl, p < 0.05), trigliceryde (TG) (316.7 to 220.6 mg/dl, p < 0.05), oxLDL (68.7 +/- 5.5 to 39.7 +/- 3.7 U/l, p < 0.001) and increase in high-density lipoprotein (HDL) (35.1 to 41.9 mg/dl, p < 0.05). Fibrate treatment also decreased CRP(5.81 +/- 0.26 to 5.08 +/- 0.06 mg/l, p < 0.001), PAI-1 (120.4 +/- 9.7 to 84.7 +/- 5.9 ng/ml; p < 0.05), fibrinogen (3.65 +/- 0.17 to 3.44 +/- 0.16 g/l, ns) and factor VII (159.7% +/- 56.7 to 141% +/- 42.4, ns). The micronized fenofibrate at a daily dose of 267 mg demonstrated a highly beneficial effect on all lipid parameters and advantageous influence on inflammatory and thrombogenic plasma risk factors in patients with dyslipidemia HLPIIb.
authors.affiliation: Department of Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland.
authors.forename: Bogusław
authors.initials: B
authors.lastname: Okopień
authors.forename: Maciej
authors.initials: M
authors.lastname: Haberka
authors.forename: Andrzej
authors.initials: A
authors.lastname: Madej
authors.forename: Dariusz
authors.initials: D
authors.lastname: Belowski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Labuzek
authors.forename: Robert
authors.initials: R
authors.lastname: Krysiak
authors.forename: Marek
authors.initials: M
authors.lastname: Zieliński
authors.forename: Marcin
authors.initials: M
authors.lastname: Basiak
authors.forename: Zbigniew S
authors.initials: ZS
authors.lastname: Herman
mesh_terms: D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D050171:Dyslipidemias / Q000097:blood; D005167:Factor VII / Q000378:metabolism*; D005260:Female; D011345:Fenofibrate / Q000737:chemistry / Q000494:pharmacology*; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood*; D000960:Hypolipidemic Agents / Q000737:chemistry / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008832:Microchemistry; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D017395:Plasminogen Activator Inhibitor 1; C099252:oxidized low density lipoprotein; D005167:Factor VII; D005340:Fibrinogen; D002097:C-Reactive Protein; D011345:Fenofibrate